New venture round boosts Raven's cancer work

South San Francisco-based Raven biotechnologies has pocketed $48.3 million from its fourth round of venture capital. Vulcan Capital led the round. Raven has been working to develop monoclonal antibody therapeutics for treating cancer.

- read this press release for more

ALSO: Alinea Pharmaceuticals has raised $45 million in its first round of venture capital. MPM Capital Ventures led the round with Flagship Ventures and Burrill & Co. joining in. Alinea is working on a treatment for diabetic neuropathy, a condition involving nerve damage among diabetics. Private Equity Week reports that Alinea is already working on a second round of $25 million. Report

PLUS: Light Sciences Oncology has raised $35 million in its first round. Report

FINALLY: Aerie Pharmaceuticals raised $21 million in its first round. Release

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.